A drug already proven effective in battling breast cancer could help men win against prostate cancer, ... New treatment dramatically halts prostate cancer progression: ... 2021, 5:49 p.m. ET ...

Brachytherapy is deemed successful as a new form of radiation therapy ... 2021 at 1:45 PM EDT ... doctors are calling a minimally invasive approach to prostate cancer treatment ...

More information: Ruchi Ghildiyal et al, Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance, Cancer Res (2021). DOI: 10.1158 ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Why prostate cancer is so hard to study—and how researchers are ... So far in 2021, the US has seen roughly 248,530 new cases and about 34,130 ... development of new treatments and saving ...

People are living longer, and with prostate cancer, the number of new cases increases dramatically with age – from 0.2% among men under 50; to 2% for men over 50; 5% over 60; and 9% over 70.

Three new prostate cancer biomarkers have been identified that improve the visibility of cancer cells used by pathologists to grade the disease’s severity, which could help determine which ...

A new study has found that for some patients with treatment-resistant prostate cancer, a new treatment can “block" the messages cancer uses to “hijack" white blood cells.

Patients helping researchers to advance treatments for prostate cancer Date: August 23, 2021 Source: Monash University Summary: Researchers have established one of the world's largest collections ...

New clues to prostate cancer Why aggressive subtype can resist treatment Date: January 15, 2021 Source: Flinders University Summary: New research has identified a new mechanism in which prostate ...

A new study has identified a potential breakthrough treatment to combat aggressive forms of prostate cancer. Researcher Luke Selth reacts to the findings.

Doctors are reporting improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumor cells.